GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Institutional Ownership

Medicenna Therapeutics (TSX:MDNA) Institutional Ownership : 0.05% (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medicenna Therapeutics's institutional ownership is 0.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medicenna Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medicenna Therapeutics's Float Percentage Of Total Shares Outstanding is 22.40%.


Medicenna Therapeutics Institutional Ownership Historical Data

The historical data trend for Medicenna Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Institutional Ownership Chart

Medicenna Therapeutics Historical Data

The historical data trend for Medicenna Therapeutics can be seen below:

2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31
Institutional Ownership 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05

Medicenna Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines